Targeting somatostatin receptors: Preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET

Journal of Nuclear Medicine

Volumn 52, Issue 9, 2011, Pages 1441-1448

  Leyton, Julius ^a   Iddon, Lisa ^b   Perumal, Meg ^a   Indrevoll, Bard ^c   Glaser, Matthias ^b   Robins, Edward ^b   George, Andrew J T ^a   Cuthbertson, Alan ^c   Luthra, Sajinder K ^b   Aboagye, Eric O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c GE HEALTHCARE   (Norway)

Author keywords

18F fluoroethyltriazole Tyr3 octreotate; Neuroendocrine; Octreotide; Positron emission tomography; Somatostatin receptor

Indexed keywords

FLUORINE 18; OCTREOTATE DERIVATIVE; OCTREOTATE F 18; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; IN VITRO STUDY; LIVER; MOUSE; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; FEMALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 80052615497     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.088906     Document Type: Article

References (40)

1. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol. 2008;9:61-72.
2. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
3. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29:934-943.
4. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
5. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198. (Pubitemid 29362641)
6. Garcea G, Ong SL, Maddern GJ. The current role of PET-CT in the characterization of hepatobiliary malignancies. HPB (Oxford). 2009;11:4-17.
7. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med. 1995;36:1825-1835.
8. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282. (Pubitemid 30167697)
9. 123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
10. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-247. (Pubitemid 43817847)
11. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437-441.
12. Schottelius M, Reubi JC, Eltschinger V, Schwaiger M, Wester HJ. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. J Med Chem. 2005;48:2778-2789. (Pubitemid 40548093)
13. Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med. 1995;36:2315-2325.
14. Jamar F, Barone R, Mathieu I, et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518. (Pubitemid 36559829)
15. 111In]-DTPAOC SPECT: first results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42-48.
16. 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:48-52.
17. 64Cu-DOTA- TOC) for imaging somatostatin receptor-expressing tumors. Ann Nucl Med. 2009;23:559-567.
18. 18F] fluoropropionyl-(D)phe1)- octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol. 1994;21:819-825.
19. 18F-fluorine. J Nucl Med. 2010;51:454-461.
20. 18F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res. 2004;10:3593-3606.
21. 18F-FDG. Cancer. 2008;112:2447-2455.
22. 111In]DTPA- octreotide. J Nucl Med. 2006;47:566-573.
23. Marik J, Sutcliffe JL. Click for PET: rapid preparation of [F-18]fluoropeptides using Cu-I catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett. 2006;47:6681-6684. (Pubitemid 44176106)
24. Glaser M, Årstad E. "Click labeling" with 2-[18f]fluoroethylazide for positron emission tomography. Bioconjug Chem. 2007;18:989-993. (Pubitemid 47010823)
25. Glaser M, Robins E. 'Click labeling' in PET radiochemistry. J Labelled Comp Radiopharm. 2009;52:407-414.
26. Ramenda T, Kniess T, Bergmann R, Steinbach J, Wuest F. Radiolabeling of proteins with fluorine-18 via click chemistry. Chem Commun (Camb). 2009;7521-7523.
27. 18F] fluoroethyl triazole labelled [Tyr3]octreotate analogues using click chemistry. Bioorg Med Chem Lett. 2011;21:3122-3127.
28. Taylor JE, Theveniau MA, Bashirzadeh R, Reisine T, Eden PA. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides. 1994;15:1229-1236. (Pubitemid 24337076)
29. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555-1577.
30. 18F]fluorothymidine positron emission tomography. Cancer Res. 2006;66:7621-7629.
31. Bates CM, Kegg H, Grady S. Expression of somatostatin receptors 1 and 2 in the adult mouse kidney. Regul Pept. 2004;119:11-20. (Pubitemid 38482097)
32. Froidevaux S, Heppeler A, Eberle AN, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology. 2000;141:3304-3312. (Pubitemid 32269019)
33. Veronese FM, Mero A. The impact of PEGylation on biological therapies. Bio-Drugs. 2008;22:315-329.
34. 111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med. 2003;44:1315-1321.
35. Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, De Jong M. Localisation and mechanism of renal retention of radiolabeled somatostatin analogues. Eur J Nucl Med Mol Imaging. 2005;32:1136-1143. (Pubitemid 41355939)
36. De Jong MW, Pinas IM, Van Eijck J. Delayed interval delivery after intrauterine infection and immature birth of twin 1: a case report and literature review. Eur J Obstet Gynecol Reprod Biol. 1995;63:91-94.
37. 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28:761-768.
38. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212. (Pubitemid 28130048)
39. Vora JP, Owens DR, Ryder R, Atiea J, Luzio S, Hayes TM. Effect of somatostatin on renal function. Br Med J (Clin Res Ed). 1986;292:1701-1702. (Pubitemid 16097898)
40. Szepeshazi K, Schally AV, Halmos G, et al. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res. 2002;62:781-788. (Pubitemid 34126954)